Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs GSK 1437173A (Primary) ; GSK 2321138A (Primary)
  • Indications Herpes zoster; Influenza A virus infections
  • Focus Pharmacodynamics; Registrational
  • Acronyms ZOSTER-004
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 26 Sep 2017 Primary endpoint has been met. (FLU Haemagglutination Inhibition (HI) Antibody Titers [ Time Frame: At Day 21 post vaccination ]), according to results published in the Journal of Infectious Diseases.
    • 26 Sep 2017 Primary endpoint has been met. (Adjusted Geometric Mean ELISA Concentrations of Anti-gE Antibodies [ Time Frame: At one month post-dose 2 (Month 3 for GSK1437173A + GSK2321138A group and Month 5 for Control group) ]), according to results published in the Journal of Infectious Diseases.
    • 26 Sep 2017 Primary endpoint has been met. (Vaccine Response for Anti-gE Humoral Immunogenicity [ Time Frame: At one month post-dose 2 (Month 3) ]), according to results published in the Journal of Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top